C Number:

Study Gender:

PWG Approval Date

PA10X: Statistical Analysis of Non-Neoplastic Lesions Test Compound: Benzo(a)pyrene CAS Number: 50-32-8 Date Report Requested: 06/12/2019 Time Report Requested: 12:30:07 Lab: BRT with ILS

I10353

Female See web page for date of PWG Approval

Date Report Requested: 06/12/2019 Time Report Requested: 12:30:07 Lab: BRT with ILS

Female : Immunopath									
	Treatment Groups (mg/kg)								
	0	2	5	9	19	38	75	150	
Disposition Summary									
Animals Initially In Study	8	8	8	8	8	8	8	8	
Early Deaths									
Scheduled Deaths									
Scheduled sacrifice, terminal (SD 28)	8	8	8	8	8	8	8	8	
Number of Animals Examined	8	8	8	8	8	8	8	8	
ALIMENTARY SYSTEM									
ESOPHAGUS	(0)	(0)	(1)	(0)	(0)	(0)	(0)	(0)	
INFLAMMATION; CHRONIC			1 (100%)						
CARDIOVASCULAR SYSTEM									
None									
ENDOCRINE SYSTEM									
ADRENAL GLAND	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
ACCESSORY ADRENOCORTICAL NODULE			1 (12.5%)	1 (12.5%)	1 (12.5%)	1 (12.5%)	1 (12.5%)		
SUBCAPSULAR; HYPERPLASIA	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)	7 (87.5%)	
GENERAL BODY SYSTEM			·						
None									
GENITAL SYSTEM									
OVARY	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
CORPUS LUTEUM; DECREASED NUMBER	0 **						4 (50%) *	8 (100%) **	

Date Report Requested: 06/12/2019 Time Report Requested: 12:30:07 Lab: BRT with ILS

Female : Immunopath									
	Treatment Groups (mg/kg)								
-	0	2	5	9	19	38	75	150	
HEMATOLYMPHOID SYSTEM									
LYMPH NODE, MESENTERIC	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
PARACORTEX; INCREASED AREA	0 **		1 (12.5%)	2 (25%)	2 (25%)	8 (100%) **	5 (62.5%) *	7 (87.5%) **	
PARACORTEX; LYMPHOCYTE; INCREASED NUMBER	0 **		1 (12.5%)	2 (25%)	2 (25%)	8 (100%) **	5 (62.5%) *	7 (87.5%) **	
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
CONGESTION			1 (12.5%)		1 (12.5%)				
PERIARTERIOLAR LYMPHOID SHEATH; DECREASED AREA; FOCAL		1 (12.5%)							
RED PULP; DECREASED HEMATOPOIETIC CELLS	0 **							2 (25%)	
PERIARTERIOLAR LYMPHOID SHEATH; DECREASED LYMPHOCYTES; FOCAL		1 (12.5%)					1 (12.5%)		
PERIARTERIOLAR LYMPHOID SHEATH; DECREASED LYMPHOCYTES	0 **				2 (25%)	3 (37.5%)	3 (37.5%)	4 (50%) *	
FOLLICLES; GERMINAL CENTER; DECREASED NUMBER	0 **	1 (12.5%)	1 (12.5%)	1 (12.5%)	3 (37.5%)	5 (62.5%) *	8 (100%) **	8 (100%) **	
MARGINAL ZONE; INCREASED AREA		1 (12.5%)							
FOLLICLES; GERMINAL CENTER; INCREASED NUMBER			1 (12.5%)						
WHITE PULP; PIGMENTED MACROPHAGE; INCREASED NUMBER	1 (12.5%)								
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
CORTEX/MEDULLA RATIO - DECREASED	0 **	1 (12.5%)		2 (25%)	3 (37.5%)	6 (75%) **	7 (87.5%) **	8 (100%) **	
CYST	7 (87.5%)	4 (50%)	5 (62.5%)	5 (62.5%)	6 (75%)	7 (87.5%)	6 (75%)	6 (75%)	
CORTEX; DECREASED AREA	0 **	. ,	. ,	2 (25%)	3 (37.5%)	6 (75%) **	7 (87.5%) **	7 (87.5%) **	
MEDULLA; DECREASED AREA	0 **			. ,	2 (25%)	2 (25%)	2 (25%)	6 (75%) **	
CORTEX; LYMPHOCYTE; DECREASED NUMBER	0 **			2 (25%)	3 (37.5%)	6 (75%) **	7 (87.5%) **	8 (100%) **	
MEDULLA; LYMPHOCYTE; DECREASED NUMBER	0 **			1 (12.5%)	2 (25%)	2 (25%)	3 (37.5%)	8 (100%) **	
ECTOPIC TISSUE	2 (25%)					1 (12.5%)		1 (12.5%)	

Date Report Requested: 06/12/2019 Time Report Requested: 12:30:07 Lab: BRT with ILS

Female : Immunopath									
	Treatment Groups (mg/kg)								
	0	2	5	9	19	38	75	150	
CORTEX; APOPTOTIC LYMPHOCYTE; INCREASED NUMBER	0 **				1 (12.5%)	2 (25%)	1 (12.5%)	8 (100%) **	
MEDULLA; APOPTOTIC LYMPHOCYTE; INCREASED NUMBER	0 **						1 (12.5%)	7 (87.5%) **	
CAPSULE; MONONUCLEAR CELL; INFILTRATE, CELLULAR				1 (12.5%)					
CAPSULE; INFILTRATION, ADIPOCYTES								1 (12.5%)	
INTEGUMENTARY SYSTEM None									
MUSCULOSKELETAL SYSTEM None									
NERVOUS SYSTEM None									
RESPIRATORY SYSTEM		-							
LUNG CONGESTION	(8)	(8)	(8)	(8) 4 (50%) *	(8)	(8) 2 (25%)	(8) 2 (25%)	(8)	
HEMORRHAGE INFLAMMATION; CHRONIC-ACTIVE	1 (12.5%)			1 (12.5%)	1 (12.5%)	1 (12.5%)		1 (12.5%) 1 (12.5%)	
SPECIAL SENSES SYSTEM None									
URINARY SYSTEM									
KIDNEY PELVIS; INFILTRATE, CELLULAR; MIXED	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8) 1 (12.5%)	
INFILTRATE, CELLULAR; MIXED NEPHROPATHY		2 (25%)	2 (25%) 1 (12.5%)	2 (25%) 1 (12.5%)	1 (12.5%)	1 (12.5%)	1 (12.5%) 1 (12.5%)	1 (12.5%)	

Date Report Requested: 06/12/2019 Time Report Requested: 12:30:07 Lab: BRT with ILS

LEGEND

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

All trend and pairwise p-values are reported as one-sided.

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

** END OF REPORT **